will with recently programs, on Scott. clinical starting updates reported you, Today, provide paltusotine. Thank I
as to As of not Both start of treatment a approval in generally paltusotine the therefore, was who switch was and and designed to also PATHFNDR for in well endpoints, patients a with with paltusotine to studies prespecified shown in spectrum a acromegaly. studied the Phase treated efficacy safety We, primary all from met paltusotine and seek first-line intend PATHFNDR be as for are to PATHFINDER-X might tolerated. and broad PATHFNDR-X. injected medications reminder, the those efficacy III SRLs who paltusotine program as treatment studied evaluate secondary might currently and of patients
IGF-X patients These all key was of the end reduced Besides from meeting reported baselines occurred the with sustained points, throughout durably with treatment We XX% paltusotine. were notable weeks. to occurring of in in PATHFNDR-X. that IGF-X top most reductions it results treated most effect recently rapidly untreated was period. the line in X elevated declines These just patients the from X
symptom Significant improvements in associated documented in controlled X now independent paltusotine with compared acromegaly control trials. to major have placebo been
are we to their symptoms into excited rich very discussed, during further daily trials. database our explore on which the basis previously As a patients reported
June. reporting analyses, to have already Endocrine from which Meeting With in the will perform interesting additional able at we PATHFNDR-X, the we Society be been database
look acromegaly have day-to-day on the and difference in frequency that wondered with forward the paltusotine might we to for a at time this in daily treated patients result of long-acting exacerbation plague We soon whether injections, meeting. a with reporting symptom oral long many
paltusotine We Acrobat with this be from now of long-term data treated will II years. for been have also updated presenting the number cohort in our open-label study. the X from study late-breaking extension A Phase ADVANCE participants over
than a just as symptoms the The rigorously disease well more the overall as acromegaly rapid allow convenient The for current suggests substitute standard injection. of that to is fully physicians control paltusotine of in data PATHFNDR-X paltusotine IGF-X paltusotine set dose than an biochemical to a activity. much reach agents, of has notably the case user-friendly, been for markers represents care. observed oral first-line effective patients of current and lot the response could Unlike faster demonstrated
administered is at on agent already these simple the dealing after a due, standard one worry to last not would whether acromegaly and next dealing the side equipment could paradigm the need People a nor last schedule new receptor-based completely oral therapy. injections. short, prevent of next occur effects with associated paltusotine, may care. how need not current burdens and medication that represent with was or expense paltusotine need course or With injection the that correctly, would pitfalls, special for the self-administer take A around lives not if acromegaly In pain one of home. injection are with the the often their once-daily one it until to somatostatin will unneeded might to to and
the carcinoid line top flushing. controlled also SRL and entry. the second indication, promising study Participants or has syndrome, disease, syndrome Paltusotine one to either and key therapy diarrhea This open-label were March, participants of both reported enrolled were or from or trial. Phase who of willing prior treatment to shown In symptomatic of and target standard wash care on actively results. with experienced untreated we the out carcinoid to symptoms II results naive
severe Paltusotine was treatment-related generally well adverse or in evaluated events. trial doses serious with this the no tolerated at
December. the pharmacokinetics and both bowel consistent in severity observed see we We to was the this and in expected reported and addition, prior we frequency results meaningful initial movements episodes, what last from In reductions population patient experience. with with significant consistent of flushing
intensity was reductions also sustained these period. symptoms These X-week occurred of reduced the treatment throughout rapidly paltusotine Importantly, the quite were and by
design. intend on with dose, align had you on study and III timing we've discussions. carcinoid II once to endpoint discuss these We the Phase a III to FDA Phase Phase forward details, look We including the updating to registrational the data syndrome
ACTH discussed, atumelnant, a our or treatment development Cushing's and of which congenital Scott adrenal hyperplasia, clinical in in receptor disease. is is second both antagonist compound once-daily investigational CAH, the development for oral As
interrupt ACTH. steroid The is complications excessive sole that disease excessive by to to order the glands and it receptor signaling, steroid diseases. the the therefore, driven natural, of ACTH the found is fundamentally progression adrenals. only cause these the both states, is target because of in the the in source It in That adrenal and is pathologic exposure production the sole are is mediator of clinical or MCX ACTH to receptor
cortisol these production. low of a approximately XX-hydroxyprogesterone of like adrenal resulting patients overproduction XX,XXX levels adrenals of in patients androgens cortisol responsible by in adrenal for The that The as pituitary hypothalamus CAH, the excess ACTH, like is ACTH. cortisol affects responds also in for cortex, disorder turn, known enzyme U.S. causes levels and the to overstimulation the classic critical lack AX. high and a in This precursors producing androstenedione, lead genetic atumelnant These indication
should doses serious produce complications and CAH is cause Because glucocorticoid but The adulthood. medical into be adverse for should and low adrenal's low, life, cannot childhood progressing very replacement beginning doses effects. patients not through exogenous hyperandrogenemia replacement many causes in utero, cortisol, required these
As weeks. without balance This adrenal find in attempt are serious a result, androgen strike in adrenal between to these medical glucocorticoid, excess production fundamental high atumelnant data edema, right coming many super to and is other to of thereby, associated and reducing and doses elevated highlights physicians as of II with the Phase challenge to such levels look from dose problems. to the effects the use suppress find our of difficult glucocorticoids. achieve an androgens right which the adrenal physiologic in lower It initial it frequently effects These ACTH this androgen glucocorticoid controls elevated yet treating production. minimizing forward glucocorticoids doses effects. gain, adverse a effectively studies showing to disease bone a balance loss elevated the of very glucose, host approach side weight We is this necessary causing believe
eliminate designed adrenal, who be to level lower stimulation Atumelnant patients are should their and or excessive output. of hyperandrogenemia even or therapy-related steroid doses the adverse Once adrenal controlled, avoid ACTH lowering effects. at reduce was thereby reduce adrenal to dose of is taking glucocorticoid androgen able the
this CAH. overdriven pathologic the is androgen adrenals chokepoint ACTH ACTH Remember, turned And single which only output receptor seen the the system is in at might ACTH receptor off. adrenal be the a the in means which drives by
cohort Our open-label for study Phase in is CAH months. X sequential and ongoing dose of atumelnant safety pharmacokinetics II dosed evaluating
using primarily well In evaluating androstenedione, hydroxyprogesterone. is androgenic AX, the or addition, as we pharmacodynamics. precursor in biomarker, XX measured are And CAH, this as cortisol the
adrenal unchanged and response these can observe androgen excessive course evaluate pretrial patients treatment expect output. time any of reduce the glucocorticoid reduction know doses, that the by In reflected is continued atumelnant to exposure at adrenal reproducibly The reliably steroids once itself. in to to studies, we eliminate and study as biomarkers. to can dose our future we durability their The goal so glucocorticoids compound we of
atumelnant Meeting initial Endocrine a we the include the at June. cohorts. late-breaking upcoming Scott first CAH cohort in full will X study the Society of will patients As data dose not the in of but This from comprise mentioned, presenting data will be subset
early results directional CAH. in information will Phase atumelnant also the these disease for expect in from will We us at the plans same that II single-center help trial give Initial developmental guide presented Cushing's be meeting. data will
it review With financials. that, Marc hand to now to over will I the
